Intelligence / Healthtech / PMA Approvals / Siemens Healthcare Diagnostics, INC.
Approvalsdevice change approved (PMA)26 Aug 2026
Siemens Healthcare Diagnostics, INC.
26 Aug 2026: Device change approved (PMA) · Atellica IM Total PSA II (tPSAII). Recorded in the openFDA device PMA data.
- Decided
- 26 Aug 2026
- Device
- Atellica IM Total PSA II (tPSAII)
- Specialty
- Immunology
- Type
- Supplement (Normal 180 Day Track)
- Reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Reference
- P240021 S001
- Location
- Tarrytown, NY
What this signal means
A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.
- Cardiovascular leads with 53 of 120, then Pathology (15).
- 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Siemens Healthcare Diagnostics, INC.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for Siemens Healthcare Diagnostics, INC. in our registers.
6 NovSiemens Healthcare Diagnostics, Inc.device cleared · HealthtechApprovals5 NovSiemens Healthcare Diagnostics INC.won a public contract ($542K) · HealthtechProcurement7 OctSiemens Healthcare Diagnostics, INC.Class II recall · HealthtechQuality26 AugSiemens Healthcare Diagnostics, INC.Class II recall · HealthtechQuality26 AugSiemens Healthcare Diagnostics, INC.Class II recall · HealthtechQuality
Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.